These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 38769886

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial.
    Li C, Tang X, Zhou Z, Sun L, Lu M, Zhou W, Yang S, Zheng W, Yu H, Tan W, Zhang J, Zhang Y, Kong Y, Xu J.
    Clin Rheumatol; 2024 Nov; 43(11):3457-3467. PubMed ID: 39279018
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP.
    Arthritis Res Ther; 2017 Nov 22; 19(1):256. PubMed ID: 29166924
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
    Brunner HI, Ruperto N, Ramanan AV, Horneff G, Minden K, Calvo Penades I, Alexeeva E, Cleary G, Stern SM, Kone-Paut I, Maldonado Velázquez MDR, Rabinovich CE, Remesal A, Silva CA, Nikishina I, Zucchetto M, Brockwell L, Gordon O, Nagel S, De Benedetti F, PRINTO and PRCSG Investigators.
    Rheumatology (Oxford); 2024 Sep 01; 63(9):2535-2546. PubMed ID: 38552315
    [Abstract] [Full Text] [Related]

  • 8. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.
    Brunner HI, Chen C, Bovis F, De Benedetti F, Espada G, Joos R, Akikusa J, Chaitow J, Boteanu AL, Kimura Y, Rietschel C, Siri D, Smolewska E, Schmeling H, Brown DE, Martini A, Lovell DJ, Huang B, Ruperto N, Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group.
    Arthritis Care Res (Hoboken); 2021 Sep 01; 73(9):1264-1274. PubMed ID: 32702212
    [Abstract] [Full Text] [Related]

  • 9. Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review.
    Chantarogh S, Vilaiyuk S, Tim-Aroon T, Worawichawong S.
    BMC Nephrol; 2017 May 12; 18(1):159. PubMed ID: 28499374
    [Abstract] [Full Text] [Related]

  • 10. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T.
    J Rheumatol; 2014 Apr 12; 41(4):759-67. PubMed ID: 24634205
    [Abstract] [Full Text] [Related]

  • 11. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey.
    Shenoi S, Nanda K, Schulert GS, Bohnsack JF, Cooper AM, Edghill B, Gillispie-Taylor MC, Goldberg B, Halyabar O, Mason TG, Ronis T, Schneider R, Vehe RK, Onel K, Childhood Arthritis and Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis Workgroup.
    Pediatr Rheumatol Online J; 2019 Jul 22; 17(1):48. PubMed ID: 31331351
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.
    Nishimura K, Hara R, Umebayashi H, Takei S, Iwata N, Imagawa T, Shimizu M, Tomiita M, Seko N, Kitawaki T, Yokota S.
    Mod Rheumatol; 2021 Jan 22; 31(1):226-234. PubMed ID: 32552266
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
    Pacharapakornpong T, Vallibhakara SA, Lerkvaleekul B, Vilaiyuk S.
    Rheumatol Int; 2017 Feb 22; 37(2):251-255. PubMed ID: 27798725
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.
    Frampton JE.
    Paediatr Drugs; 2013 Dec 22; 15(6):515-31. PubMed ID: 24155139
    [Abstract] [Full Text] [Related]

  • 19. Tocilizumab for treating juvenile idiopathic arthritis.
    Turnier JL, Brunner HI.
    Expert Opin Biol Ther; 2016 Dec 22; 16(4):559-66. PubMed ID: 26848760
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.